A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors

NCT07554196 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: HH-101 (0.3 mg/kg)
DRUG: HH-101 (1 mg/kg )
DRUG: HH-101 (3 mg/kg )
DRUG: HH-101 (10 mg/kg)

Sponsor

Huahui Health